<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01640951</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457A2304E1</org_study_id>
    <secondary_id>2012-000985-39</secondary_id>
    <nct_id>NCT01640951</nct_id>
  </id_info>
  <brief_title>4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis</brief_title>
  <official_title>A Multicenter, Double-blind and Open Label, 4 Year Extension Study of Subcutaneous Secukinumab in Prefilled Syringes, Assessing Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Treated With Either a Fixed Dose Regimen or on a Retreatment at Start of Relapse Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CAIN457A2304E1 was an extension study to two phase III studies, CAIN457A2304 and CAIN457A2307
      (core studies). This extension study planned to collect up to four years of long-term safety,
      tolerability and efficacy data of secukinumab in both the fixed interval regimen and the
      retreatment at start of relapse regimen. All subjects who completed the full study treatment
      period (52 weeks) in the cores studies CAIN457A2304 and CAIN457A2307 were eligible to
      participate in this extension study. In this extension study, the prefilled syringe (PFS)
      liquid formulation of secukinumab was used.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 16, 2012</start_date>
  <completion_date type="Actual">May 4, 2017</completion_date>
  <primary_completion_date type="Actual">May 4, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term Safety and Tolerability of Secukinumab</measure>
    <time_frame>Week 268</time_frame>
    <description>Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260</measure>
    <time_frame>Week 52, Week 104, Week 156, Week 208, Week 260</time_frame>
    <description>PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area * area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260</measure>
    <time_frame>Week 52, Week 104, Week 156, Week 208, Week 260</time_frame>
    <description>PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area * area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260</measure>
    <time_frame>Baseline, Week 52, Week 104, Week 156, Week 208, Week 260</time_frame>
    <description>PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area * area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260</measure>
    <time_frame>Week 52, Week 104, Week 156, Week 208, Week 260</time_frame>
    <description>The IGA mod 2011 is a static scale, i.e., it refers exclusively to the participant's disease state at the time of the assessments and does not attempt a comparison to any of the participant's previous disease states at prior visits. The score ranges from 0 (clear) to 4 (severe). The score 0 is clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 is severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260</measure>
    <time_frame>Baseline, Week 52, Week 104, Week 156, Week 208, Week 260</time_frame>
    <description>The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260</measure>
    <time_frame>Week 52, Week 104, Week 156, Week 208, Week 260</time_frame>
    <description>The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156</measure>
    <time_frame>Baseline, Week 52, Week 104, Week 156</time_frame>
    <description>ED-5Q: Participant rated questionnaire to assess health related quality of life in terms of a single utility score. Five domains are assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each with three possible score: 1 indicates no problems, better state of health; 3 indicates worst state of health (example &quot;confined to bed&quot;) A visual analog scale (VAS) assesses the health status from 0 (worst possible health state) to 100 (best possible health state)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Anti-drug Antibodies (ADA)</measure>
    <time_frame>Week 268</time_frame>
    <description>The development of anti-secunimubab anti-bodies will decrease a participant's ability to respond to secukinumab treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Experiencing a Relapse</measure>
    <time_frame>Week 260</time_frame>
    <description>Relapse is defined as greater than 50% loss of the maximal PASI improvement from baseline.
PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Experiencing a Rebound</measure>
    <time_frame>Up to Week 264 (8 weeks post last dose)</time_frame>
    <description>Rebound of disease is defined as a worsening of PASI of &gt; 125% of the value at baseline (core study), or new pustular, erythrodermic or more inflammatory psoriasis occurring within 8 weeks of stopping therapy (i.e., if this definition was fulfilled at more than 8 weeks after last study treatment administration, this was defined as rebound like event).
PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">675</enrollment>
  <condition>Moderate to Severe Chronic Plaque-Type Psoriasis</condition>
  <arm_group>
    <arm_group_label>AIN457 150 mg - Fixed Interval (FI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 s.c. Secukinumab 150 mg Pre-filled seringue (PFS) injection + 1 s.c. Placebo (PBO) Secukinumab PFS injection every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIN457 150 mg - Start of relapse (SoR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Start of relapse: 1 s.c. Secukinumab 150 mg PFS injection + 1 s.c. PBO Secukinumab PFS injection every 4 weeks
Otherwise: 2 s.c. PBO Secukinumab PFS injections every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIN457 300 mg - Fixed Interval (FI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 s.c. Secukinumab 150 mg PFS injections every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIN457 300 mg - Start of Relapse (SoR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Start of relapse: 2 s.c. Secukinumab 150 mg PFS injection every 4 weeks
Otherwise: 2 s.c. PBO Secukinumab PFS injections every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIN457 300 mg - Open Label (OL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open Label - Secukinumab 300mg every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AIN457 150 mg</intervention_name>
    <description>(1 injection per dose) and placebo to Secukinumab 150 mg</description>
    <arm_group_label>AIN457 150 mg - Fixed Interval (FI)</arm_group_label>
    <arm_group_label>AIN457 150 mg - Start of relapse (SoR)</arm_group_label>
    <other_name>Secukinumab 150 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AIN457 300 mg</intervention_name>
    <description>Secukinumab 150 mg (2 injections per dose)</description>
    <arm_group_label>AIN457 300 mg - Fixed Interval (FI)</arm_group_label>
    <arm_group_label>AIN457 300 mg - Start of Relapse (SoR)</arm_group_label>
    <arm_group_label>AIN457 300 mg - Open Label (OL)</arm_group_label>
    <other_name>Secukinumab 300 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>AIN457 150 mg - Fixed Interval (FI)</arm_group_label>
    <arm_group_label>AIN457 150 mg - Start of relapse (SoR)</arm_group_label>
    <arm_group_label>AIN457 300 mg - Start of Relapse (SoR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be able to understand and communicate with the investigator and comply
             with the requirements of the study and must give a written, signed and dated informed
             consent before any study related activity is performed. Where relevant, a legal
             representative will also sign the informed consent according to local laws and
             regulations.

          2. Subjects who complete Week 52 of study CAIN457A2304 or complete Week 40 of study
             CAIN457A2307

          3. Subjects expected to benefit from participation in the extension study, as assessed by
             the subject and investigator

        Exclusion Criteria:

          1. A protocol deviation in the core studies which according to the investigator will
             prevent the meaningful analysis of the extension study for the individual subject

          2. Ongoing use of prohibited psoriasis or non-psoriasis treatments. Time period from last
             use of prohibited treatments in the core study to first dose of study drug in this
             extension study.

          3. Subjects expected to be exposed to an undue safety risk if participating in the trial

          4. Current severe progressive or uncontrolled disease which in the judgment of the
             investigator renders the subject unsuitable for the trial

          5. Plans for administration of live vaccines during the study period

          6. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive hCG laboratory test (&gt;10 mIU/mL).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <zip>61820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Verona</city>
        <state>New Jersey</state>
        <zip>07044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goodlettsville</city>
        <state>Tennessee</state>
        <zip>37072-2301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1231</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1404</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno - Bohunice</city>
        <state>Czech Republic</state>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hradec Kralove</city>
        <state>CZE</state>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague 8</city>
        <state>CZE</state>
        <zip>180 81</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novy Jicin</city>
        <zip>741 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague 10</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antony</city>
        <zip>92160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice Cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pierre-Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Wildbad</city>
        <zip>75323</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bochum</city>
        <zip>44793</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buchholz I. D. Nordheide</city>
        <zip>21244</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dippoldiswalde-Schmiedeberg</city>
        <zip>01744</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duesseldorf</city>
        <zip>D-40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duisburg</city>
        <zip>47166</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22391</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuppertal</city>
        <zip>42103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siena</city>
        <state>SI</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya-city</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kisarazu</city>
        <state>Chiba</state>
        <zip>292-8535</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>815-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitakyushu-city</city>
        <state>Fukuoka</state>
        <zip>800-0296</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maebashi city</city>
        <state>Gunma</state>
        <zip>371 8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Asahikawa-city</city>
        <state>Hokkaido</state>
        <zip>078-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo-city</city>
        <state>Hokkaido</state>
        <zip>060-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka-city</city>
        <state>Osaka</state>
        <zip>550-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shimotsuke-city</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>102-8798</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hachioji-city</city>
        <state>Tokyo</state>
        <zip>193-0944</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-265</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>60 529</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>308205</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <state>Slovak Republic</state>
        <zip>040 15</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <zip>04011</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poprad</city>
        <zip>05845</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Svidnik</city>
        <zip>089 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zilina</city>
        <zip>01207</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leytonstone</city>
        <state>London</state>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2WB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Blackpool</city>
        <zip>FY3 7EN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leicester</city>
        <zip>LE7 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poole</city>
        <zip>BH15 2JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <state>VNM</state>
        <zip>700000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hanoi</city>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hanoi</city>
        <zip>1000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <zip>7000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
    <country>Vietnam</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>India</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2012</study_first_submitted>
  <study_first_submitted_qc>July 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2012</study_first_posted>
  <results_first_submitted>April 23, 2018</results_first_submitted>
  <results_first_submitted_qc>April 24, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 25, 2018</results_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Plaque</keyword>
  <keyword>Inflammatory skin disease</keyword>
  <keyword>Scaly patches</keyword>
  <keyword>AIN457</keyword>
  <keyword>Secukinumab</keyword>
  <keyword>Moderate to Severe Plaque-type Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>675 subjects from the core studies (CAIN457A2304 and CAIN457A2307) were enrolled at 112 sites. Subjects enrolled in the secukinumab 300 mg Open-Label (OL) arm came only from the CAIN457A2307 study, as such they were partial responders at Week 12, while all other subjects in the extension were PASI 75 responders at Week 12 in the core study.</recruitment_details>
      <pre_assignment_details>At Week 156, subjects who rolled over from the CAIN457A2304 study were unblinded and provided an option to switch to one of the treatment options described below upon investigator judgment; subjects from the CAIN457A2307 study could administer study drug at home every 4 weeks, but were required to come for office visits every 12-16 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AIN150FI</title>
          <description>AIN457 150 mg - Fixed Interval (FI)</description>
        </group>
        <group group_id="P2">
          <title>AIN150 FI_AIN300 FI</title>
          <description>AIN457 150 mg FI switch to AIN457 300 mg FI (150 mg FI SW)</description>
        </group>
        <group group_id="P3">
          <title>AIN300 FI</title>
          <description>AIN457 300 mg - Fixed Interval (FI)</description>
        </group>
        <group group_id="P4">
          <title>AIN150 SoR</title>
          <description>AIN457 150 mg - Start of Relapse (SoR)</description>
        </group>
        <group group_id="P5">
          <title>AIN150 SOR_AIN300 FI</title>
          <description>AIN457 150 mg SoR switch to AIN457 300 mg FI (150 mg SoR SW)</description>
        </group>
        <group group_id="P6">
          <title>AIN300 SoR</title>
          <description>AIN457 300 mg - Start of Relapse (SoR)</description>
        </group>
        <group group_id="P7">
          <title>AIN300 SoR _ AIN300 FI</title>
          <description>AIN457 300 mg SoR switch to AIN457 300 mg FI (300 mg SoR SW)</description>
        </group>
        <group group_id="P8">
          <title>AIN300 OL</title>
          <description>AIN457 300 mg Open-label (OL)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="168"/>
                <participants group_id="P4" count="55"/>
                <participants group_id="P5" count="95"/>
                <participants group_id="P6" count="60"/>
                <participants group_id="P7" count="112"/>
                <participants group_id="P8" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="126"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="82"/>
                <participants group_id="P6" count="13"/>
                <participants group_id="P7" count="94"/>
                <participants group_id="P8" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="45"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="47"/>
                <participants group_id="P7" count="18"/>
                <participants group_id="P8" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject/Guardian decision</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AIN150FI</title>
          <description>AIN457 150 mg - Fixed Interval (FI)</description>
        </group>
        <group group_id="B2">
          <title>AIN150 FI_AIN300 FI</title>
          <description>AIN457 150 mg FI switch to AIN457 300 mg FI (150 mg FI SW)</description>
        </group>
        <group group_id="B3">
          <title>AIN300 FI</title>
          <description>AIN457 300 mg - Fixed Interval (FI)</description>
        </group>
        <group group_id="B4">
          <title>AIN150 SoR</title>
          <description>AIN457 150 mg - Start of Relapse (SoR)</description>
        </group>
        <group group_id="B5">
          <title>AIN150 SOR_AIN300 FI</title>
          <description>AIN457 150 mg SoR switch to AIN457 300 mg FI (150 mg SoR SW)</description>
        </group>
        <group group_id="B6">
          <title>AIN300 SoR</title>
          <description>AIN457 300 mg - Start of Relapse (SoR)</description>
        </group>
        <group group_id="B7">
          <title>AIN300 SoR _ AIN300 FI</title>
          <description>AIN457 300 mg SoR switch to AIN457 300 mg FI (300 mg SoR SW)</description>
        </group>
        <group group_id="B8">
          <title>AIN300 OL</title>
          <description>AIN457 300 mg Open-label (OL)</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="77"/>
            <count group_id="B2" value="75"/>
            <count group_id="B3" value="168"/>
            <count group_id="B4" value="55"/>
            <count group_id="B5" value="95"/>
            <count group_id="B6" value="60"/>
            <count group_id="B7" value="112"/>
            <count group_id="B8" value="33"/>
            <count group_id="B9" value="675"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.3" spread="13.24"/>
                    <measurement group_id="B2" value="46.0" spread="12.03"/>
                    <measurement group_id="B3" value="48.5" spread="12.54"/>
                    <measurement group_id="B4" value="42.7" spread="12.23"/>
                    <measurement group_id="B5" value="48.0" spread="12.13"/>
                    <measurement group_id="B6" value="45.2" spread="12.08"/>
                    <measurement group_id="B7" value="44.6" spread="13.09"/>
                    <measurement group_id="B8" value="46.5" spread="13.99"/>
                    <measurement group_id="B9" value="45.9" spread="12.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="35"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="231"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="67"/>
                    <measurement group_id="B6" value="42"/>
                    <measurement group_id="B7" value="77"/>
                    <measurement group_id="B8" value="21"/>
                    <measurement group_id="B9" value="444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="26"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="123"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="132"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="68"/>
                    <measurement group_id="B6" value="45"/>
                    <measurement group_id="B7" value="84"/>
                    <measurement group_id="B8" value="29"/>
                    <measurement group_id="B9" value="528"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Long-term Safety and Tolerability of Secukinumab</title>
        <description>Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC)</description>
        <time_frame>Week 268</time_frame>
        <population>Safety Set. All subjects who took at least one dose of study treatment during the extension treatment period. A subject with multiple adverse events within a primary system organ class was counted only once in the total row. Deaths up to 28 days after the last dose are included. Only descriptive analysis done.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN150FI</title>
            <description>AIN457 150 mg - Fixed Interval (FI)</description>
          </group>
          <group group_id="O2">
            <title>AIN150 FI_AIN300 FI</title>
            <description>AIN457 150 mg FI switch to AIN457 300 mg FI (150 mg FI SW)</description>
          </group>
          <group group_id="O3">
            <title>AIN300 FI</title>
            <description>AIN457 300 mg - Fixed Interval (FI)</description>
          </group>
          <group group_id="O4">
            <title>AIN150 SoR</title>
            <description>AIN457 150 mg - Start of Relapse (SoR)</description>
          </group>
          <group group_id="O5">
            <title>AIN150 SOR_AIN300 FI</title>
            <description>AIN457 150 mg SoR switch to AIN457 300 mg FI (150 mg SoR SW)</description>
          </group>
          <group group_id="O6">
            <title>AIN300 SoR</title>
            <description>AIN457 300 mg - Start of Relapse (SoR)</description>
          </group>
          <group group_id="O7">
            <title>AIN300 SoR _ AIN300 FI</title>
            <description>AIN457 300 mg SoR switch to AIN457 300 mg FI (300 mg SoR SW)</description>
          </group>
          <group group_id="O8">
            <title>AIN300 OL</title>
            <description>AIN457 300 mg Open-label (OL)</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Safety and Tolerability of Secukinumab</title>
          <description>Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC)</description>
          <population>Safety Set. All subjects who took at least one dose of study treatment during the extension treatment period. A subject with multiple adverse events within a primary system organ class was counted only once in the total row. Deaths up to 28 days after the last dose are included. Only descriptive analysis done.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="168"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="95"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="112"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs by Primary System Organ Class (SOC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.3"/>
                    <measurement group_id="O2" value="92.0"/>
                    <measurement group_id="O3" value="92.9"/>
                    <measurement group_id="O4" value="78.2"/>
                    <measurement group_id="O5" value="87.4"/>
                    <measurement group_id="O6" value="80.0"/>
                    <measurement group_id="O7" value="94.6"/>
                    <measurement group_id="O8" value="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs by Primary System Organ Class (SOC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8"/>
                    <measurement group_id="O2" value="24.0"/>
                    <measurement group_id="O3" value="23.8"/>
                    <measurement group_id="O4" value="16.4"/>
                    <measurement group_id="O5" value="20.0"/>
                    <measurement group_id="O6" value="18.3"/>
                    <measurement group_id="O7" value="17.0"/>
                    <measurement group_id="O8" value="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths by Primary System Organ Class (SOC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="0.6"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260</title>
        <description>PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area * area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)</description>
        <time_frame>Week 52, Week 104, Week 156, Week 208, Week 260</time_frame>
        <population>The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN150FI</title>
            <description>AIN457 150 mg - Fixed Interval (FI)</description>
          </group>
          <group group_id="O2">
            <title>AIN150 FI_AIN300 FI</title>
            <description>AIN457 150 mg FI switch to AIN457 300 mg FI (150 mg FI SW)</description>
          </group>
          <group group_id="O3">
            <title>AIN150FI (NSW+SW)</title>
            <description>AIN457 150 mg - Fixed Interval combined non-switch and switch</description>
          </group>
          <group group_id="O4">
            <title>AIN300 FI</title>
            <description>AIN457 300 mg - Fixed Interval (FI)</description>
          </group>
          <group group_id="O5">
            <title>AIN150 SoR</title>
            <description>AIN457 150 mg - Start of Relapse (SoR)</description>
          </group>
          <group group_id="O6">
            <title>AIN150 SOR_AIN300 FI</title>
            <description>AIN457 150 mg SoR switch to AIN457 300 mg FI (150 mg SoR SW)</description>
          </group>
          <group group_id="O7">
            <title>AIN300 SoR</title>
            <description>AIN457 300 mg - Start of Relapse (SoR)</description>
          </group>
          <group group_id="O8">
            <title>AIN300 SoR _ AIN300 FI</title>
            <description>AIN457 300 mg SoR switch to AIN457 300 mg FI (300 mg SoR SW)</description>
          </group>
          <group group_id="O9">
            <title>AIN300 OL</title>
            <description>AIN457 300 mg Open-label (OL)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260</title>
          <description>PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area * area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)</description>
          <population>The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="168"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="95"/>
                <count group_id="O7" value="60"/>
                <count group_id="O8" value="112"/>
                <count group_id="O9" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="151"/>
                    <count group_id="O4" value="162"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="58"/>
                    <count group_id="O8" value="111"/>
                    <count group_id="O9" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.7"/>
                    <measurement group_id="O2" value="65.3"/>
                    <measurement group_id="O3" value="67.5"/>
                    <measurement group_id="O4" value="88.9"/>
                    <measurement group_id="O5" value="38.2"/>
                    <measurement group_id="O6" value="38.9"/>
                    <measurement group_id="O7" value="51.7"/>
                    <measurement group_id="O8" value="39.6"/>
                    <measurement group_id="O9" value="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="133"/>
                    <count group_id="O4" value="152"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="34"/>
                    <count group_id="O8" value="110"/>
                    <count group_id="O9" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3"/>
                    <measurement group_id="O2" value="54.8"/>
                    <measurement group_id="O3" value="58.6"/>
                    <measurement group_id="O4" value="80.9"/>
                    <measurement group_id="O5" value="40.0"/>
                    <measurement group_id="O6" value="39.4"/>
                    <measurement group_id="O7" value="55.9"/>
                    <measurement group_id="O8" value="44.5"/>
                    <measurement group_id="O9" value="63.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="115"/>
                    <count group_id="O4" value="139"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="111"/>
                    <count group_id="O9" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0"/>
                    <measurement group_id="O2" value="49.3"/>
                    <measurement group_id="O3" value="61.7"/>
                    <measurement group_id="O4" value="78.4"/>
                    <measurement group_id="O5" value="62.5"/>
                    <measurement group_id="O6" value="35.1"/>
                    <measurement group_id="O7" value="65.0"/>
                    <measurement group_id="O8" value="41.4"/>
                    <measurement group_id="O9" value="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="132"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="87"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="100"/>
                    <count group_id="O9" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="78.3"/>
                    <measurement group_id="O3" value="78.8"/>
                    <measurement group_id="O4" value="87.9"/>
                    <measurement group_id="O5" value="63.6"/>
                    <measurement group_id="O6" value="87.4"/>
                    <measurement group_id="O7" value="41.7"/>
                    <measurement group_id="O8" value="79.0"/>
                    <measurement group_id="O9" value="61.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="122"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="79"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="87"/>
                    <count group_id="O9" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7"/>
                    <measurement group_id="O2" value="71.4"/>
                    <measurement group_id="O3" value="77.6"/>
                    <measurement group_id="O4" value="88.5"/>
                    <measurement group_id="O5" value="50.0"/>
                    <measurement group_id="O6" value="86.1"/>
                    <measurement group_id="O7" value="53.8"/>
                    <measurement group_id="O8" value="81.6"/>
                    <measurement group_id="O9" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260</title>
        <description>PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area * area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)</description>
        <time_frame>Week 52, Week 104, Week 156, Week 208, Week 260</time_frame>
        <population>The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN150FI</title>
            <description>AIN457 150 mg - Fixed Interval (FI)</description>
          </group>
          <group group_id="O2">
            <title>AIN150 FI_AIN300 FI</title>
            <description>AIN457 150 mg FI switch to AIN457 300 mg FI (150 mg FI SW)</description>
          </group>
          <group group_id="O3">
            <title>AIN150FI (NSW+SW)</title>
            <description>AIN457 150 mg - Fixed Interval combined non-switch and switch</description>
          </group>
          <group group_id="O4">
            <title>AIN300 FI</title>
            <description>AIN457 300 mg - Fixed Interval (FI)</description>
          </group>
          <group group_id="O5">
            <title>AIN150 SoR</title>
            <description>AIN457 150 mg - Start of Relapse (SoR)</description>
          </group>
          <group group_id="O6">
            <title>AIN150 SOR_AIN300 FI</title>
            <description>AIN457 150 mg SoR switch to AIN457 300 mg FI (150 mg SoR SW)</description>
          </group>
          <group group_id="O7">
            <title>AIN300 SoR</title>
            <description>AIN457 300 mg - Start of Relapse (SoR)</description>
          </group>
          <group group_id="O8">
            <title>AIN300 SoR _ AIN300 FI</title>
            <description>AIN457 300 mg SoR switch to AIN457 300 mg FI (300 mg SoR SW)</description>
          </group>
          <group group_id="O9">
            <title>AIN300 OL</title>
            <description>AIN457 300 mg Open-label (OL)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260</title>
          <description>PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area * area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)</description>
          <population>The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="168"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="95"/>
                <count group_id="O7" value="60"/>
                <count group_id="O8" value="112"/>
                <count group_id="O9" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52 / PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="151"/>
                    <count group_id="O4" value="162"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="58"/>
                    <count group_id="O8" value="111"/>
                    <count group_id="O9" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5"/>
                    <measurement group_id="O2" value="98.7"/>
                    <measurement group_id="O3" value="94.0"/>
                    <measurement group_id="O4" value="98.8"/>
                    <measurement group_id="O5" value="80.0"/>
                    <measurement group_id="O6" value="86.3"/>
                    <measurement group_id="O7" value="91.4"/>
                    <measurement group_id="O8" value="88.3"/>
                    <measurement group_id="O9" value="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 / PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="151"/>
                    <count group_id="O4" value="162"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="58"/>
                    <count group_id="O8" value="111"/>
                    <count group_id="O9" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.8"/>
                    <measurement group_id="O2" value="38.7"/>
                    <measurement group_id="O3" value="50.3"/>
                    <measurement group_id="O4" value="68.5"/>
                    <measurement group_id="O5" value="12.7"/>
                    <measurement group_id="O6" value="11.6"/>
                    <measurement group_id="O7" value="19.0"/>
                    <measurement group_id="O8" value="12.6"/>
                    <measurement group_id="O9" value="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 / PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="151"/>
                    <count group_id="O4" value="162"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="58"/>
                    <count group_id="O8" value="111"/>
                    <count group_id="O9" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6"/>
                    <measurement group_id="O2" value="16.0"/>
                    <measurement group_id="O3" value="23.8"/>
                    <measurement group_id="O4" value="43.8"/>
                    <measurement group_id="O5" value="3.6"/>
                    <measurement group_id="O6" value="2.1"/>
                    <measurement group_id="O7" value="8.6"/>
                    <measurement group_id="O8" value="3.6"/>
                    <measurement group_id="O9" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 / PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="133"/>
                    <count group_id="O4" value="152"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="34"/>
                    <count group_id="O8" value="110"/>
                    <count group_id="O9" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.3"/>
                    <measurement group_id="O2" value="84.9"/>
                    <measurement group_id="O3" value="86.5"/>
                    <measurement group_id="O4" value="96.7"/>
                    <measurement group_id="O5" value="80.0"/>
                    <measurement group_id="O6" value="87.2"/>
                    <measurement group_id="O7" value="88.2"/>
                    <measurement group_id="O8" value="85.5"/>
                    <measurement group_id="O9" value="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 / PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="133"/>
                    <count group_id="O4" value="152"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="34"/>
                    <count group_id="O8" value="110"/>
                    <count group_id="O9" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7"/>
                    <measurement group_id="O2" value="23.3"/>
                    <measurement group_id="O3" value="33.8"/>
                    <measurement group_id="O4" value="64.5"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="9.6"/>
                    <measurement group_id="O7" value="14.7"/>
                    <measurement group_id="O8" value="18.2"/>
                    <measurement group_id="O9" value="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 / PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="133"/>
                    <count group_id="O4" value="152"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="34"/>
                    <count group_id="O8" value="110"/>
                    <count group_id="O9" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3"/>
                    <measurement group_id="O2" value="6.8"/>
                    <measurement group_id="O3" value="16.5"/>
                    <measurement group_id="O4" value="43.4"/>
                    <measurement group_id="O5" value="10.0"/>
                    <measurement group_id="O6" value="1.1"/>
                    <measurement group_id="O7" value="5.9"/>
                    <measurement group_id="O8" value="4.5"/>
                    <measurement group_id="O9" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 / PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="115"/>
                    <count group_id="O4" value="139"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="111"/>
                    <count group_id="O9" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="86.7"/>
                    <measurement group_id="O3" value="91.3"/>
                    <measurement group_id="O4" value="97.1"/>
                    <measurement group_id="O5" value="93.8"/>
                    <measurement group_id="O6" value="88.3"/>
                    <measurement group_id="O7" value="85.0"/>
                    <measurement group_id="O8" value="90.1"/>
                    <measurement group_id="O9" value="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 / PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="115"/>
                    <count group_id="O4" value="139"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="111"/>
                    <count group_id="O9" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="17.3"/>
                    <measurement group_id="O3" value="32.2"/>
                    <measurement group_id="O4" value="61.9"/>
                    <measurement group_id="O5" value="31.3"/>
                    <measurement group_id="O6" value="10.6"/>
                    <measurement group_id="O7" value="30.0"/>
                    <measurement group_id="O8" value="10.8"/>
                    <measurement group_id="O9" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 / PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="115"/>
                    <count group_id="O4" value="139"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="111"/>
                    <count group_id="O9" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0"/>
                    <measurement group_id="O2" value="8.0"/>
                    <measurement group_id="O3" value="20.9"/>
                    <measurement group_id="O4" value="41.7"/>
                    <measurement group_id="O5" value="6.3"/>
                    <measurement group_id="O6" value="4.3"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="3.6"/>
                    <measurement group_id="O9" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208 / PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="132"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="87"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="100"/>
                    <count group_id="O9" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="97.1"/>
                    <measurement group_id="O3" value="98.1"/>
                    <measurement group_id="O4" value="97.0"/>
                    <measurement group_id="O5" value="72.7"/>
                    <measurement group_id="O6" value="98.9"/>
                    <measurement group_id="O7" value="100.0"/>
                    <measurement group_id="O8" value="95.0"/>
                    <measurement group_id="O9" value="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208 / PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="132"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="87"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="100"/>
                    <count group_id="O9" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4"/>
                    <measurement group_id="O2" value="49.3"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="65.9"/>
                    <measurement group_id="O5" value="27.3"/>
                    <measurement group_id="O6" value="64.4"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="53.0"/>
                    <measurement group_id="O9" value="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208 / PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="132"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="87"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="100"/>
                    <count group_id="O9" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="20.3"/>
                    <measurement group_id="O3" value="23.1"/>
                    <measurement group_id="O4" value="43.2"/>
                    <measurement group_id="O5" value="9.1"/>
                    <measurement group_id="O6" value="23.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="24.0"/>
                    <measurement group_id="O9" value="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 / PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="122"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="79"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="87"/>
                    <count group_id="O9" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="96.4"/>
                    <measurement group_id="O3" value="97.6"/>
                    <measurement group_id="O4" value="97.5"/>
                    <measurement group_id="O5" value="100.0"/>
                    <measurement group_id="O6" value="97.5"/>
                    <measurement group_id="O7" value="100.0"/>
                    <measurement group_id="O8" value="93.1"/>
                    <measurement group_id="O9" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 / PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="122"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="79"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="87"/>
                    <count group_id="O9" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7"/>
                    <measurement group_id="O2" value="46.4"/>
                    <measurement group_id="O3" value="48.2"/>
                    <measurement group_id="O4" value="66.4"/>
                    <measurement group_id="O5" value="30.0"/>
                    <measurement group_id="O6" value="57.0"/>
                    <measurement group_id="O7" value="7.7"/>
                    <measurement group_id="O8" value="54.0"/>
                    <measurement group_id="O9" value="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 / PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="122"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="79"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="87"/>
                    <count group_id="O9" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="22.4"/>
                    <measurement group_id="O4" value="41.0"/>
                    <measurement group_id="O5" value="10.0"/>
                    <measurement group_id="O6" value="29.1"/>
                    <measurement group_id="O7" value="7.7"/>
                    <measurement group_id="O8" value="18.4"/>
                    <measurement group_id="O9" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260</title>
        <description>PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area * area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)</description>
        <time_frame>Baseline, Week 52, Week 104, Week 156, Week 208, Week 260</time_frame>
        <population>The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN150FI</title>
            <description>AIN457 150 mg - Fixed Interval (FI)</description>
          </group>
          <group group_id="O2">
            <title>AIN150 FI_AIN300 FI</title>
            <description>AIN457 150 mg FI switch to AIN457 300 mg FI (150 mg FI SW)</description>
          </group>
          <group group_id="O3">
            <title>AIN150FI (NSW+SW)</title>
            <description>AIN457 150 mg - Fixed Interval combined non-switch and switch</description>
          </group>
          <group group_id="O4">
            <title>AIN300 FI</title>
            <description>AIN457 300 mg - Fixed Interval (FI)</description>
          </group>
          <group group_id="O5">
            <title>AIN150 SoR</title>
            <description>AIN457 150 mg - Start of Relapse (SoR)</description>
          </group>
          <group group_id="O6">
            <title>AIN150 SOR_AIN300 FI</title>
            <description>AIN457 150 mg SoR switch to AIN457 300 mg FI (150 mg SoR SW)</description>
          </group>
          <group group_id="O7">
            <title>AIN300 SoR</title>
            <description>AIN457 300 mg - Start of Relapse (SoR)</description>
          </group>
          <group group_id="O8">
            <title>AIN300 SoR _ AIN300 FI</title>
            <description>AIN457 300 mg SoR switch to AIN457 300 mg FI (300 mg SoR SW)</description>
          </group>
          <group group_id="O9">
            <title>AIN300 OL</title>
            <description>AIN457 300 mg Open-label (OL)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260</title>
          <description>PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area * area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)</description>
          <population>The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="168"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="95"/>
                <count group_id="O7" value="60"/>
                <count group_id="O8" value="112"/>
                <count group_id="O9" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="151"/>
                    <count group_id="O4" value="162"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="58"/>
                    <count group_id="O8" value="111"/>
                    <count group_id="O9" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-83.54" spread="21.744"/>
                    <measurement group_id="O2" value="-81.47" spread="16.179"/>
                    <measurement group_id="O3" value="-82.51" spread="19.147"/>
                    <measurement group_id="O4" value="-91.14" spread="13.377"/>
                    <measurement group_id="O5" value="-65.13" spread="23.452"/>
                    <measurement group_id="O6" value="-67.91" spread="21.521"/>
                    <measurement group_id="O7" value="-75.63" spread="16.970"/>
                    <measurement group_id="O8" value="-69.13" spread="18.976"/>
                    <measurement group_id="O9" value="-79.75" spread="17.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="133"/>
                    <count group_id="O4" value="152"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="34"/>
                    <count group_id="O8" value="110"/>
                    <count group_id="O9" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-78.13" spread="26.278"/>
                    <measurement group_id="O2" value="-72.47" spread="24.099"/>
                    <measurement group_id="O3" value="-75.02" spread="25.168"/>
                    <measurement group_id="O4" value="-88.48" spread="16.273"/>
                    <measurement group_id="O5" value="-63.17" spread="28.596"/>
                    <measurement group_id="O6" value="-68.40" spread="18.057"/>
                    <measurement group_id="O7" value="-67.62" spread="40.039"/>
                    <measurement group_id="O8" value="-70.98" spread="19.720"/>
                    <measurement group_id="O9" value="-76.10" spread="19.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="115"/>
                    <count group_id="O4" value="139"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="111"/>
                    <count group_id="O9" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-90.27" spread="11.543"/>
                    <measurement group_id="O2" value="-71.48" spread="19.892"/>
                    <measurement group_id="O3" value="-78.02" spread="19.576"/>
                    <measurement group_id="O4" value="-88.34" spread="15.555"/>
                    <measurement group_id="O5" value="-78.97" spread="16.709"/>
                    <measurement group_id="O6" value="-68.71" spread="18.094"/>
                    <measurement group_id="O7" value="-77.40" spread="18.714"/>
                    <measurement group_id="O8" value="-69.77" spread="18.586"/>
                    <measurement group_id="O9" value="-76.12" spread="20.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="132"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="87"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="100"/>
                    <count group_id="O9" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-87.60" spread="12.296"/>
                    <measurement group_id="O2" value="-85.06" spread="14.082"/>
                    <measurement group_id="O3" value="-85.91" spread="13.501"/>
                    <measurement group_id="O4" value="-90.46" spread="14.116"/>
                    <measurement group_id="O5" value="-72.64" spread="24.394"/>
                    <measurement group_id="O6" value="-89.36" spread="12.978"/>
                    <measurement group_id="O7" value="-74.38" spread="13.817"/>
                    <measurement group_id="O8" value="-85.25" spread="17.018"/>
                    <measurement group_id="O9" value="-79.12" spread="16.827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="122"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="79"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="87"/>
                    <count group_id="O9" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-88.75" spread="10.928"/>
                    <measurement group_id="O2" value="-84.10" spread="15.012"/>
                    <measurement group_id="O3" value="-85.68" spread="13.867"/>
                    <measurement group_id="O4" value="-90.06" spread="14.639"/>
                    <measurement group_id="O5" value="-76.20" spread="17.418"/>
                    <measurement group_id="O6" value="-89.40" spread="12.763"/>
                    <measurement group_id="O7" value="-78.13" spread="10.197"/>
                    <measurement group_id="O8" value="-85.48" spread="17.116"/>
                    <measurement group_id="O9" value="-81.47" spread="21.335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Investigator’s Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260</title>
        <description>The IGA mod 2011 is a static scale, i.e., it refers exclusively to the participant’s disease state at the time of the assessments and does not attempt a comparison to any of the participant’s previous disease states at prior visits. The score ranges from 0 (clear) to 4 (severe). The score 0 is clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 is severe.</description>
        <time_frame>Week 52, Week 104, Week 156, Week 208, Week 260</time_frame>
        <population>The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN150FI</title>
            <description>AIN457 150 mg - Fixed Interval (FI)</description>
          </group>
          <group group_id="O2">
            <title>AIN150 FI_AIN300 FI</title>
            <description>AIN457 150 mg FI switch to AIN457 300 mg FI (150 mg FI SW)</description>
          </group>
          <group group_id="O3">
            <title>AIN150FI (NSW+SW)</title>
            <description>AIN457 150 mg - Fixed Interval combined non-switch and switch</description>
          </group>
          <group group_id="O4">
            <title>AIN300 FI</title>
            <description>AIN457 300 mg - Fixed Interval (FI)</description>
          </group>
          <group group_id="O5">
            <title>AIN150 SoR</title>
            <description>AIN457 150 mg - Start of Relapse (SoR)</description>
          </group>
          <group group_id="O6">
            <title>AIN150 SOR_AIN300 FI</title>
            <description>AIN457 150 mg SoR switch to AIN457 300 mg FI (150 mg SoR SW)</description>
          </group>
          <group group_id="O7">
            <title>AIN300 SoR</title>
            <description>AIN457 300 mg - Start of Relapse (SoR)</description>
          </group>
          <group group_id="O8">
            <title>AIN300 SoR _ AIN300 FI</title>
            <description>AIN457 300 mg SoR switch to AIN457 300 mg FI (300 mg SoR SW)</description>
          </group>
          <group group_id="O9">
            <title>AIN300 OL</title>
            <description>AIN457 300 mg Open-label (OL)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Investigator’s Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260</title>
          <description>The IGA mod 2011 is a static scale, i.e., it refers exclusively to the participant’s disease state at the time of the assessments and does not attempt a comparison to any of the participant’s previous disease states at prior visits. The score ranges from 0 (clear) to 4 (severe). The score 0 is clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 is severe.</description>
          <population>The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="168"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="95"/>
                <count group_id="O7" value="60"/>
                <count group_id="O8" value="112"/>
                <count group_id="O9" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52 / IGA 0/1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="151"/>
                    <count group_id="O4" value="165"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="60"/>
                    <count group_id="O8" value="111"/>
                    <count group_id="O9" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2"/>
                    <measurement group_id="O2" value="50.7"/>
                    <measurement group_id="O3" value="55.0"/>
                    <measurement group_id="O4" value="69.1"/>
                    <measurement group_id="O5" value="20.0"/>
                    <measurement group_id="O6" value="20.0"/>
                    <measurement group_id="O7" value="28.3"/>
                    <measurement group_id="O8" value="19.8"/>
                    <measurement group_id="O9" value="42.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 / IGA 0/1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="133"/>
                    <count group_id="O4" value="152"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="34"/>
                    <count group_id="O8" value="110"/>
                    <count group_id="O9" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7"/>
                    <measurement group_id="O2" value="30.1"/>
                    <measurement group_id="O3" value="39.8"/>
                    <measurement group_id="O4" value="66.4"/>
                    <measurement group_id="O5" value="20.0"/>
                    <measurement group_id="O6" value="16.0"/>
                    <measurement group_id="O7" value="17.6"/>
                    <measurement group_id="O8" value="17.3"/>
                    <measurement group_id="O9" value="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 / IGA 0/1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="115"/>
                    <count group_id="O4" value="139"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="94"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="111"/>
                    <count group_id="O9" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                    <measurement group_id="O2" value="21.3"/>
                    <measurement group_id="O3" value="35.7"/>
                    <measurement group_id="O4" value="56.8"/>
                    <measurement group_id="O5" value="37.5"/>
                    <measurement group_id="O6" value="14.9"/>
                    <measurement group_id="O7" value="25.0"/>
                    <measurement group_id="O8" value="15.3"/>
                    <measurement group_id="O9" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208 / IGA 0/1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="132"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="87"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="100"/>
                    <count group_id="O9" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                    <measurement group_id="O2" value="47.1"/>
                    <measurement group_id="O3" value="50.5"/>
                    <measurement group_id="O4" value="62.1"/>
                    <measurement group_id="O5" value="41.7"/>
                    <measurement group_id="O6" value="63.2"/>
                    <measurement group_id="O7" value="8.3"/>
                    <measurement group_id="O8" value="52.0"/>
                    <measurement group_id="O9" value="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 / IGA 0/1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="120"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="79"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="87"/>
                    <count group_id="O9" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2"/>
                    <measurement group_id="O2" value="48.2"/>
                    <measurement group_id="O3" value="50.6"/>
                    <measurement group_id="O4" value="65.0"/>
                    <measurement group_id="O5" value="40.0"/>
                    <measurement group_id="O6" value="58.2"/>
                    <measurement group_id="O7" value="30.8"/>
                    <measurement group_id="O8" value="54.0"/>
                    <measurement group_id="O9" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260</title>
        <description>The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions</description>
        <time_frame>Baseline, Week 52, Week 104, Week 156, Week 208, Week 260</time_frame>
        <population>The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN150FI</title>
            <description>AIN457 150 mg - Fixed Interval (FI)</description>
          </group>
          <group group_id="O2">
            <title>AIN150 FI_AIN300 FI</title>
            <description>AIN457 150 mg FI switch to AIN457 300 mg FI (150 mg FI SW)</description>
          </group>
          <group group_id="O3">
            <title>AIN150FI (NSW+SW)</title>
            <description>AIN457 150 mg - Fixed Interval combined non-switch and switch</description>
          </group>
          <group group_id="O4">
            <title>AIN300 FI</title>
            <description>AIN457 300 mg - Fixed Interval (FI)</description>
          </group>
          <group group_id="O5">
            <title>AIN150 SoR</title>
            <description>AIN457 150 mg - Start of Relapse (SoR)</description>
          </group>
          <group group_id="O6">
            <title>AIN150 SOR_AIN300 FI</title>
            <description>AIN457 150 mg SoR switch to AIN457 300 mg FI (150 mg SoR SW)</description>
          </group>
          <group group_id="O7">
            <title>AIN300 SoR</title>
            <description>AIN457 300 mg - Start of Relapse (SoR)</description>
          </group>
          <group group_id="O8">
            <title>AIN300 SoR _ AIN300 FI</title>
            <description>AIN457 300 mg SoR switch to AIN457 300 mg FI (300 mg SoR SW)</description>
          </group>
          <group group_id="O9">
            <title>AIN300 OL</title>
            <description>AIN457 300 mg Open-label (OL)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260</title>
          <description>The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions</description>
          <population>The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="168"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="95"/>
                <count group_id="O7" value="60"/>
                <count group_id="O8" value="112"/>
                <count group_id="O9" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="151"/>
                    <count group_id="O4" value="164"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="60"/>
                    <count group_id="O8" value="108"/>
                    <count group_id="O9" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-77.3" lower_limit="-87.5" upper_limit="-68.3"/>
                    <measurement group_id="O2" value="-85.7" lower_limit="-90.0" upper_limit="-77.8"/>
                    <measurement group_id="O3" value="-81.8" lower_limit="-87.5" upper_limit="-75.0"/>
                    <measurement group_id="O4" value="-93.3" lower_limit="-95.5" upper_limit="-90.3"/>
                    <measurement group_id="O5" value="-65.0" lower_limit="-74.7" upper_limit="-55.6"/>
                    <measurement group_id="O6" value="-68.2" lower_limit="-75.0" upper_limit="-61.0"/>
                    <measurement group_id="O7" value="-66.7" lower_limit="-75.0" upper_limit="-52.9"/>
                    <measurement group_id="O8" value="-72.8" lower_limit="-79.0" upper_limit="-65.0"/>
                    <measurement group_id="O9" value="-79.2" lower_limit="-89.6" upper_limit="-65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="152"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="91"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="103"/>
                    <count group_id="O9" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70.8" lower_limit="-83.3" upper_limit="-63.3"/>
                    <measurement group_id="O2" value="-73.8" lower_limit="-80.4" upper_limit="-65.9"/>
                    <measurement group_id="O3" value="-73.3" lower_limit="-78.1" upper_limit="-67.3"/>
                    <measurement group_id="O4" value="-87.5" lower_limit="-93.3" upper_limit="-83.3"/>
                    <measurement group_id="O5" value="-71.9" lower_limit="-80.2" upper_limit="-58.6"/>
                    <measurement group_id="O6" value="-63.6" lower_limit="-70.8" upper_limit="-56.3"/>
                    <measurement group_id="O7" value="-68.8" lower_limit="-78.9" upper_limit="-51.8"/>
                    <measurement group_id="O8" value="-74.9" lower_limit="-81.2" upper_limit="-66.7"/>
                    <measurement group_id="O9" value="-77.2" lower_limit="-88.9" upper_limit="-62.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="113"/>
                    <count group_id="O4" value="137"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="93"/>
                    <count group_id="O7" value="21"/>
                    <count group_id="O8" value="107"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-89.3" lower_limit="-97.4" upper_limit="-81.0"/>
                    <measurement group_id="O2" value="-67.9" lower_limit="-75.0" upper_limit="-60.0"/>
                    <measurement group_id="O3" value="-75.0" lower_limit="-80.0" upper_limit="-69.3"/>
                    <measurement group_id="O4" value="-91.7" lower_limit="-93.8" upper_limit="-86.4"/>
                    <measurement group_id="O5" value="-79.6" lower_limit="-91.7" upper_limit="-58.3"/>
                    <measurement group_id="O6" value="-60.6" lower_limit="-67.7" upper_limit="-53.3"/>
                    <measurement group_id="O7" value="-73.9" lower_limit="-84.6" upper_limit="-62.5"/>
                    <measurement group_id="O8" value="-66.7" lower_limit="-74.2" upper_limit="-59.4"/>
                    <measurement group_id="O9" value="-80.0" lower_limit="-90.5" upper_limit="-61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="106"/>
                    <count group_id="O4" value="131"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="88"/>
                    <count group_id="O7" value="14"/>
                    <count group_id="O8" value="98"/>
                    <count group_id="O9" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-87.5" lower_limit="-97.4" upper_limit="-82.1"/>
                    <measurement group_id="O2" value="-81.3" lower_limit="-88.9" upper_limit="-72.4"/>
                    <measurement group_id="O3" value="-83.3" lower_limit="-89.3" upper_limit="-78.2"/>
                    <measurement group_id="O4" value="-92.1" lower_limit="-96.0" upper_limit="-88.3"/>
                    <measurement group_id="O5" value="-75.0" lower_limit="-86.1" upper_limit="-56.5"/>
                    <measurement group_id="O6" value="-85.7" lower_limit="-90.5" upper_limit="-80.1"/>
                    <measurement group_id="O7" value="-74.1" lower_limit="-85.6" upper_limit="-55.4"/>
                    <measurement group_id="O8" value="-84.6" lower_limit="-88.1" upper_limit="-78.9"/>
                    <measurement group_id="O9" value="-81.7" lower_limit="-90.5" upper_limit="-66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="118"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="79"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="85"/>
                    <count group_id="O9" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-90.9" lower_limit="-95.5" upper_limit="-76.2"/>
                    <measurement group_id="O2" value="-84.8" lower_limit="-91.7" upper_limit="-76.2"/>
                    <measurement group_id="O3" value="-86.1" lower_limit="-91.7" upper_limit="-78.3"/>
                    <measurement group_id="O4" value="-92.3" lower_limit="-95.0" upper_limit="-83.3"/>
                    <measurement group_id="O5" value="-75.0" lower_limit="-100.0" upper_limit="-44.9"/>
                    <measurement group_id="O6" value="-82.3" lower_limit="-90.6" upper_limit="-74.3"/>
                    <measurement group_id="O7" value="-63.9" lower_limit="-78.4" upper_limit="-44.4"/>
                    <measurement group_id="O8" value="-83.3" lower_limit="-89.1" upper_limit="-76.2"/>
                    <measurement group_id="O9" value="-80.0" lower_limit="-95.0" upper_limit="-59.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260</title>
        <description>The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions</description>
        <time_frame>Week 52, Week 104, Week 156, Week 208, Week 260</time_frame>
        <population>The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN150FI</title>
            <description>AIN457 150 mg - Fixed Interval (FI)</description>
          </group>
          <group group_id="O2">
            <title>AIN150 FI_AIN300 FI</title>
            <description>AIN457 150 mg FI switch to AIN457 300 mg FI (150 mg FI SW)</description>
          </group>
          <group group_id="O3">
            <title>AIN150FI (NSW+SW)</title>
            <description>AIN457 150 mg - Fixed Interval combined non-switch and switch</description>
          </group>
          <group group_id="O4">
            <title>AIN300 FI</title>
            <description>AIN457 300 mg - Fixed Interval (FI)</description>
          </group>
          <group group_id="O5">
            <title>AIN150 SoR</title>
            <description>AIN457 150 mg - Start of Relapse (SoR)</description>
          </group>
          <group group_id="O6">
            <title>AIN150 SOR_AIN300 FI</title>
            <description>AIN457 150 mg SoR switch to AIN457 300 mg FI (150 mg SoR SW)</description>
          </group>
          <group group_id="O7">
            <title>AIN300 SoR</title>
            <description>AIN457 300 mg - Start of Relapse (SoR)</description>
          </group>
          <group group_id="O8">
            <title>AIN300 SoR _ AIN300 FI</title>
            <description>AIN457 300 mg SoR switch to AIN457 300 mg FI (300 mg SoR SW)</description>
          </group>
          <group group_id="O9">
            <title>AIN300 OL</title>
            <description>AIN457 300 mg Open-label (OL)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260</title>
          <description>The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions</description>
          <population>The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="168"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="95"/>
                <count group_id="O7" value="60"/>
                <count group_id="O8" value="112"/>
                <count group_id="O9" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="152"/>
                    <count group_id="O4" value="165"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="95"/>
                    <count group_id="O7" value="60"/>
                    <count group_id="O8" value="111"/>
                    <count group_id="O9" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.7"/>
                    <measurement group_id="O2" value="57.3"/>
                    <measurement group_id="O3" value="58.6"/>
                    <measurement group_id="O4" value="72.7"/>
                    <measurement group_id="O5" value="32.7"/>
                    <measurement group_id="O6" value="34.7"/>
                    <measurement group_id="O7" value="28.3"/>
                    <measurement group_id="O8" value="41.4"/>
                    <measurement group_id="O9" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="153"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="91"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="106"/>
                    <count group_id="O9" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5"/>
                    <measurement group_id="O2" value="47.2"/>
                    <measurement group_id="O3" value="50.7"/>
                    <measurement group_id="O4" value="64.7"/>
                    <measurement group_id="O5" value="41.2"/>
                    <measurement group_id="O6" value="33.0"/>
                    <measurement group_id="O7" value="32.5"/>
                    <measurement group_id="O8" value="41.5"/>
                    <measurement group_id="O9" value="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="114"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="93"/>
                    <count group_id="O7" value="21"/>
                    <count group_id="O8" value="109"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="37.3"/>
                    <measurement group_id="O3" value="47.4"/>
                    <measurement group_id="O4" value="67.4"/>
                    <measurement group_id="O5" value="43.8"/>
                    <measurement group_id="O6" value="35.5"/>
                    <measurement group_id="O7" value="38.1"/>
                    <measurement group_id="O8" value="38.5"/>
                    <measurement group_id="O9" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="107"/>
                    <count group_id="O4" value="132"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="88"/>
                    <count group_id="O7" value="14"/>
                    <count group_id="O8" value="100"/>
                    <count group_id="O9" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.2"/>
                    <measurement group_id="O2" value="52.9"/>
                    <measurement group_id="O3" value="56.1"/>
                    <measurement group_id="O4" value="70.5"/>
                    <measurement group_id="O5" value="30.8"/>
                    <measurement group_id="O6" value="62.5"/>
                    <measurement group_id="O7" value="42.9"/>
                    <measurement group_id="O8" value="59.0"/>
                    <measurement group_id="O9" value="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="86"/>
                    <count group_id="O4" value="119"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="79"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="87"/>
                    <count group_id="O9" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2"/>
                    <measurement group_id="O2" value="54.4"/>
                    <measurement group_id="O3" value="54.7"/>
                    <measurement group_id="O4" value="65.5"/>
                    <measurement group_id="O5" value="60.0"/>
                    <measurement group_id="O6" value="55.7"/>
                    <measurement group_id="O7" value="15.6"/>
                    <measurement group_id="O8" value="56.3"/>
                    <measurement group_id="O9" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156</title>
        <description>ED-5Q: Participant rated questionnaire to assess health related quality of life in terms of a single utility score. Five domains are assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each with three possible score: 1 indicates no problems, better state of health; 3 indicates worst state of health (example “confined to bed”) A visual analog scale (VAS) assesses the health status from 0 (worst possible health state) to 100 (best possible health state)</description>
        <time_frame>Baseline, Week 52, Week 104, Week 156</time_frame>
        <population>The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN150FI</title>
            <description>AIN457 150 mg - Fixed Interval (FI)</description>
          </group>
          <group group_id="O2">
            <title>AIN150 FI_AIN300 FI</title>
            <description>AIN457 150 mg FI switch to AIN457 300 mg FI (150 mg FI SW)</description>
          </group>
          <group group_id="O3">
            <title>AIN150FI (NSW+SW)</title>
            <description>AIN457 150 mg - Fixed Interval combined non-switch and switch</description>
          </group>
          <group group_id="O4">
            <title>AIN300 FI</title>
            <description>AIN457 300 mg - Fixed Interval (FI)</description>
          </group>
          <group group_id="O5">
            <title>AIN150 SoR</title>
            <description>AIN457 150 mg - Start of Relapse (SoR)</description>
          </group>
          <group group_id="O6">
            <title>AIN150 SOR_AIN300 FI</title>
            <description>AIN457 150 mg SoR switch to AIN457 300 mg FI (150 mg SoR SW)</description>
          </group>
          <group group_id="O7">
            <title>AIN300 SoR</title>
            <description>AIN457 300 mg - Start of Relapse (SoR)</description>
          </group>
          <group group_id="O8">
            <title>AIN300 SoR _ AIN300 FI</title>
            <description>AIN457 300 mg SoR switch to AIN457 300 mg FI (300 mg SoR SW)</description>
          </group>
          <group group_id="O9">
            <title>AIN300 OL</title>
            <description>AIN457 300 mg Open-label (OL)</description>
          </group>
        </group_list>
        <measure>
          <title>EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156</title>
          <description>ED-5Q: Participant rated questionnaire to assess health related quality of life in terms of a single utility score. Five domains are assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each with three possible score: 1 indicates no problems, better state of health; 3 indicates worst state of health (example “confined to bed”) A visual analog scale (VAS) assesses the health status from 0 (worst possible health state) to 100 (best possible health state)</description>
          <population>The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="168"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="95"/>
                <count group_id="O7" value="60"/>
                <count group_id="O8" value="112"/>
                <count group_id="O9" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="151"/>
                    <count group_id="O4" value="165"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="93"/>
                    <count group_id="O7" value="58"/>
                    <count group_id="O8" value="110"/>
                    <count group_id="O9" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8" spread="137.47"/>
                    <measurement group_id="O2" value="57.0" spread="137.79"/>
                    <measurement group_id="O3" value="63.0" spread="137.30"/>
                    <measurement group_id="O4" value="115.8" spread="666.41"/>
                    <measurement group_id="O5" value="40.2" spread="94.91"/>
                    <measurement group_id="O6" value="76.9" spread="222.97"/>
                    <measurement group_id="O7" value="41.3" spread="140.42"/>
                    <measurement group_id="O8" value="98.8" spread="359.93"/>
                    <measurement group_id="O9" value="60.9" spread="74.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="153"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="89"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="106"/>
                    <count group_id="O9" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" spread="122.96"/>
                    <measurement group_id="O2" value="62.4" spread="156.21"/>
                    <measurement group_id="O3" value="60.6" spread="140.91"/>
                    <measurement group_id="O4" value="118.5" spread="689.52"/>
                    <measurement group_id="O5" value="29.5" spread="70.63"/>
                    <measurement group_id="O6" value="152.9" spread="902.21"/>
                    <measurement group_id="O7" value="46.7" spread="142.85"/>
                    <measurement group_id="O8" value="77.2" spread="150.86"/>
                    <measurement group_id="O9" value="54.3" spread="84.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="114"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="91"/>
                    <count group_id="O7" value="21"/>
                    <count group_id="O8" value="107"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0" spread="114.81"/>
                    <measurement group_id="O2" value="52.1" spread="115.04"/>
                    <measurement group_id="O3" value="55.2" spread="114.53"/>
                    <measurement group_id="O4" value="125.3" spread="677.23"/>
                    <measurement group_id="O5" value="45.1" spread="102.64"/>
                    <measurement group_id="O6" value="140.3" spread="778.86"/>
                    <measurement group_id="O7" value="13.7" spread="25.16"/>
                    <measurement group_id="O8" value="109.5" spread="373.51"/>
                    <measurement group_id="O9" value="68.1" spread="96.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Anti-drug Antibodies (ADA)</title>
        <description>The development of anti-secunimubab anti-bodies will decrease a participant's ability to respond to secukinumab treatment.</description>
        <time_frame>Week 268</time_frame>
        <population>The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only descriptive analysis done.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN150FI</title>
            <description>AIN457 150 mg - Fixed Interval (FI)</description>
          </group>
          <group group_id="O2">
            <title>AIN150 FI_AIN300 FI</title>
            <description>AIN457 150 mg FI switch to AIN457 300 mg FI (150 mg FI SW)</description>
          </group>
          <group group_id="O3">
            <title>AIN300 FI</title>
            <description>AIN457 300 mg - Fixed Interval (FI)</description>
          </group>
          <group group_id="O4">
            <title>AIN150 SoR</title>
            <description>AIN457 150 mg - Start of Relapse (SoR)</description>
          </group>
          <group group_id="O5">
            <title>AIN150 SOR_AIN300 FI</title>
            <description>AIN457 150 mg SoR switch to AIN457 300 mg FI (150 mg SoR SW)</description>
          </group>
          <group group_id="O6">
            <title>AIN300 SoR</title>
            <description>AIN457 300 mg - Start of Relapse (SoR)</description>
          </group>
          <group group_id="O7">
            <title>AIN300 SoR _ AIN300 FI</title>
            <description>AIN457 300 mg SoR switch to AIN457 300 mg FI (300 mg SoR SW)</description>
          </group>
          <group group_id="O8">
            <title>AIN300 OL</title>
            <description>AIN457 300 mg Open-label (OL)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Anti-drug Antibodies (ADA)</title>
          <description>The development of anti-secunimubab anti-bodies will decrease a participant's ability to respond to secukinumab treatment.</description>
          <population>The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only descriptive analysis done.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="168"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="95"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="112"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Experiencing a Relapse</title>
        <description>Relapse is defined as greater than 50% loss of the maximal PASI improvement from baseline.
PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement.</description>
        <time_frame>Week 260</time_frame>
        <population>The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN150FI</title>
            <description>AIN457 150 mg - Fixed Interval (FI)</description>
          </group>
          <group group_id="O2">
            <title>AIN150 FI_AIN300 FI</title>
            <description>AIN457 150 mg FI switch to AIN457 300 mg FI (150 mg FI SW)</description>
          </group>
          <group group_id="O3">
            <title>AIN300 FI</title>
            <description>AIN457 300 mg - Fixed Interval (FI)</description>
          </group>
          <group group_id="O4">
            <title>AIN150 SoR</title>
            <description>AIN457 150 mg - Start of Relapse (SoR)</description>
          </group>
          <group group_id="O5">
            <title>AIN150 SOR_AIN300 FI</title>
            <description>AIN457 150 mg SoR switch to AIN457 300 mg FI (150 mg SoR SW)</description>
          </group>
          <group group_id="O6">
            <title>AIN300 SoR</title>
            <description>AIN457 300 mg - Start of Relapse (SoR)</description>
          </group>
          <group group_id="O7">
            <title>AIN300 SoR _ AIN300 FI</title>
            <description>AIN457 300 mg SoR switch to AIN457 300 mg FI (300 mg SoR SW)</description>
          </group>
          <group group_id="O8">
            <title>AIN300 OL</title>
            <description>AIN457 300 mg Open-label (OL)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Experiencing a Relapse</title>
          <description>Relapse is defined as greater than 50% loss of the maximal PASI improvement from baseline.
PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement.</description>
          <population>The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="168"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="95"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="112"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.2"/>
                    <measurement group_id="O2" value="40.0"/>
                    <measurement group_id="O3" value="19.6"/>
                    <measurement group_id="O4" value="61.8"/>
                    <measurement group_id="O5" value="52.6"/>
                    <measurement group_id="O6" value="43.3"/>
                    <measurement group_id="O7" value="56.3"/>
                    <measurement group_id="O8" value="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Experiencing a Rebound</title>
        <description>Rebound of disease is defined as a worsening of PASI of &gt; 125% of the value at baseline (core study), or new pustular, erythrodermic or more inflammatory psoriasis occurring within 8 weeks of stopping therapy (i.e., if this definition was fulfilled at more than 8 weeks after last study treatment administration, this was defined as rebound like event).
PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement.</description>
        <time_frame>Up to Week 264 (8 weeks post last dose)</time_frame>
        <population>The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN150FI</title>
            <description>AIN457 150 mg - Fixed Interval (FI)</description>
          </group>
          <group group_id="O2">
            <title>AIN150 FI_AIN300 FI</title>
            <description>AIN457 150 mg FI switch to AIN457 300 mg FI (150 mg FI SW)</description>
          </group>
          <group group_id="O3">
            <title>AIN300 FI</title>
            <description>AIN457 300 mg - Fixed Interval (FI)</description>
          </group>
          <group group_id="O4">
            <title>AIN150 SoR</title>
            <description>AIN457 150 mg - Start of Relapse (SoR)</description>
          </group>
          <group group_id="O5">
            <title>AIN150 SOR_AIN300 FI</title>
            <description>AIN457 150 mg SoR switch to AIN457 300 mg FI (150 mg SoR SW)</description>
          </group>
          <group group_id="O6">
            <title>AIN300 SoR</title>
            <description>AIN457 300 mg - Start of Relapse (SoR)</description>
          </group>
          <group group_id="O7">
            <title>AIN300 SoR _ AIN300 FI</title>
            <description>AIN457 300 mg SoR switch to AIN457 300 mg FI (300 mg SoR SW)</description>
          </group>
          <group group_id="O8">
            <title>AIN300 OL</title>
            <description>AIN457 300 mg Open-label (OL)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Experiencing a Rebound</title>
          <description>Rebound of disease is defined as a worsening of PASI of &gt; 125% of the value at baseline (core study), or new pustular, erythrodermic or more inflammatory psoriasis occurring within 8 weeks of stopping therapy (i.e., if this definition was fulfilled at more than 8 weeks after last study treatment administration, this was defined as rebound like event).
PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement.</description>
          <population>The full analysis set (FAS), which consisted of all participants with an observed value, was considered. Only patients with evaluable data at each time point were analyzed for that time point. Only descriptive analysis done.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="168"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="95"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="112"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="5.1" upper_limit="22.8"/>
                    <measurement group_id="O2" value="5.8" lower_limit="1.9" upper_limit="14.9"/>
                    <measurement group_id="O3" value="5.0" lower_limit="2.2" upper_limit="10.3"/>
                    <measurement group_id="O4" value="9.4" lower_limit="2.5" upper_limit="26.2"/>
                    <measurement group_id="O5" value="1.1" lower_limit="0.1" upper_limit="7.0"/>
                    <measurement group_id="O6" value="6.9" lower_limit="1.2" upper_limit="24.2"/>
                    <measurement group_id="O7" value="10.6" lower_limit="5.7" upper_limit="18.5"/>
                    <measurement group_id="O8" value="13.0" lower_limit="3.4" upper_limit="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4 years and 7 months.</time_frame>
      <desc>Consistent with EudraCT disclosure specifications, Novartis has reported under the Serious adverse events fields &quot;number of deaths resulting from adverse events&quot; all those deaths, resulting from serious adverse events that are deemed to be causally related to treatment by the investigator.</desc>
      <group_list>
        <group group_id="E1">
          <title>Any AIN457 150 mg</title>
          <description>Any AIN457 150 mg</description>
        </group>
        <group group_id="E2">
          <title>Any AIN457 300 mg</title>
          <description>Any AIN457 300 mg</description>
        </group>
        <group group_id="E3">
          <title>Any AIN457 Dose</title>
          <description>Any AIN457 dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="144" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>AUTOIMMUNE HAEMOLYTIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>LYMPHOID TISSUE HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA SUPRAVENTRICULAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK LEFT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>CONGESTIVE CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>CORONARY OSTIAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>LONG QT SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>MYOCARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VESTIBULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>ANAL INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE POLYP</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>LEUKOPLAKIA ORAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>HEPATIC CIRRHOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>HEPATITIS ALCOHOLIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ACUTE HEPATITIS B</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>ACUTE SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>ANAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>BURSITIS INFECTIVE STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>CHRONIC TONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>EPIDIDYMITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>MENINGITIS STREPTOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>ORCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>PERITONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ALCOHOL POISONING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>BRAIN CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>LIGAMENT INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>LIMB CRUSHING INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>MENISCUS INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>SPLENIC INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>FLANK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>FOOT DEFORMITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>PSORIATIC ARTHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>SPINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>TENOSYNOVITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>BENIGN LUNG NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>BENIGN NEOPLASM OF THYROID GLAND</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>BLADDER ADENOCARCINOMA STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>CHOLANGIOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>DYSPLASTIC NAEVUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>INVASIVE DUCTAL BREAST CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ALTERED STATE OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>CARPAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>CAUDA EQUINA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>CERVICOBRACHIAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>CUBITAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>METABOLIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>NERVE COMPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>PERONEAL NERVE PALSY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>DEVICE MALFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ADJUSTMENT DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE KIDNEY INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>RENAL INFARCT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>RENAL INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>RENAL TUBULAR NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>URETEROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>ENDOMETRIOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>MENOMETRORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>PROSTATOMEGALY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>UTERINE POLYP</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>VULVA CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>LUNG DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>PULMONARY CAVITATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYMPTOM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>THORACIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>DERMATITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>ALCOHOL USE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC DILATATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>VARICOSE VEIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="449" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="542" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>DENTAL CARIES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>SEASONAL ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>FOLLICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>FURUNCLE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="185" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="216" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>ORAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>TINEA PEDIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>TONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>TOOTH ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ARTHROPOD BITE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>LIGAMENT SPRAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>MUSCLE STRAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>DYSLIPIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>HYPERCHOLESTEROLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>PSORIATIC ARTHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>SINUS CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ACNE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>ACTINIC KERATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>DERMATITIS CONTACT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="543"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

